Πρόσφατες και σημαντικότερες δημοσιεύσεις  

1. Αξιολόγηση της Νεφρικής Λειτουργίας σε ασθενείς με κίνδυνο εμφάνισης συνδρόμου Λύσης ΄Ογκου
2. A non-interventional ,post authorization safely study , to continous monitor safety and pregnancy outcomes in a cohort of at-risk Essential Thrombocythaemia (ET) SUBJECTS EXPOSED TO Xagrid R compared to other conventional cytoreductive treatments.
3. Μία αναδρομική μη παρεμβατική μελέτη αξιολόγησης της θεραπείας με αζασιτιδίνη (azacitidine) σε ασθενείς με Ενδιάμεσου-2 και Υψηλού Κινδύνου (σύμφωνα με το Διεθνές Προγνωστικό Σύστημα -IPSS) Μυελοδυσπλαστικά Σύνδρομα.

ΔΙΕΘΝΕΙΣ ΔΗΜΟΣΙΕΥΣΕΙΣ: 

1. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A0, Vervessou E1, Katodritou E, Gika D, Terpos E, Dimopoulos MA.
Blood 2015 , Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420.

2. Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.
Kastritis E1, Kyrtsonis MC2, Morel P3, Gavriatopoulou M4, Hatjiharissi E5, Symeonidis AS6, Vassou A7, Repousis P8, Delimpasi S9, Sioni A10, Michalis E11, Michael M12, Vervessou E13, Voulgarelis M14, Tsatalas C15, Terpos E4, Dimopoulos MA4
Hematologica, 2015 Nov100(11):e446-9. doi: 10.3324/haematol.2015.124149.

3. Competing Risk Survival Analysis In Patients With Symptomatic Waldenström’s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients> 75 Years
Marie-Christine Kyrtsonis, Evdoxia Hatjiharissi, Argiris S Symeonidis, Amalia Vassou, Panagiotis Repousis, Sosana Delimpasi, Anastasia Sioni, Eurydiki Michalis, Michalis Michael, Elina Vervessou, Ekaterini Stefanoudaki, Michael Voulgarelis, Costas Tsatalas, Evangelos Terpos, Meletios A Dimopoulos
Blood, 2013

4. Primary treatment of Waldenstrom's macroglobulinemia with dexamethasone, rituximab and cyclophosphamide (DRC): final analysis of a phase II study
Meletios A Dimopoulos, Maria Roussou, Efstathios Kastritis, Evdoxia Hadjiharissi, Marie-Christine Kyrtsonis, Argiris Symeonidis, Panagiotis Repoussis, Eurydiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Maria Gavriatopoulou, Dimitra Gika, Evangelos Terpos, Konstantinos Zervas
Blood ,2012

5. No significant improvement in the outcome of patients with Waldenstrom's macroglobulinemia treated over the last 25 years
Kastritis E, Kyrtsonis MC, Hatjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas K, Michael M, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S, Gavriatopoulou M, Koulieris E, Gika D, Vervesou E, Konstantopoulos K, Kokkini G, Zomas A, Roussou P, Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K, Dimopoulos MA.
Am J Hematol. 2011PUBLICATIONS Jun;86(6):479-83. doi: 10.1002/ajh.22027. Epub 2011 Apr 20.

6. Prognostication of the high-risk WM patient.
Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Michael M, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas K, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S, Gika D, Vervesou E, Konstantopoulos K, Kokkini G, Zomas A, Roussou P, Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K, Dimopoulos MA.
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):127-9. doi: 10.3816/CLML.2011.n.028.

7. 224 Factors affecting leukemic transformation in patients with del-5q treated with lenalidomide
A Symeonidis, A Galanopoulos, E Hatzimichail, C Loukidis, A Kouraklis, Z Kartasis, G Kokkini, N Vyniou, V Pappa, M Vagia, M Protopapa, I Chaliori, E Vervessou, N Laoutaris, N Anagnostopoulos, P Panagiotidis
Leukemia Research ,2011

8. Correlation Of ATP-Binding Cassette (ABC) Transporters PGR, BCRP And ABCB6 Expression To Response To Induction Chemotherapy In Acute Myeloid Leukemia Patients
D Palaiologou, G Georgiou, T Vassilakopoulos, G Papanikolaou, N Viniou, E Variami, Y Rombos, E Vervessou, A Mpoula, G Pangalis, P Panayiotidis, N Sakellaropoulos, P Beris, M Angelopoulou
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL ,2010/6/1

9. P130 Treatment of intermediate and high risk myelodysplastic syndrome patients with azacitidine. The Hellenic experience
V Pappa, S Papageorgiou, P Tsirigotis, J Dervenoulas, K Girkas, E Papageorgiou, H Poulakidas, E Papadaki, A Galanopoulos, E Vervessou, P Panayotidis, A Zomas, A Symeonidis, T Economopoulos
Leukemia Research ,2009

10. High serum levels of angiogenic cytokines in AL amyloidosis correlates with disease features
Efstathios Kastritis, Evangelos Terpos, Mihail Mihail, Konstantinos Anargyrou, Sossana Delimpassi, Marie Christine Kyrtsonis, Evridiki Mihali, Elina Vervessou, Natalia Tzenou, Panagiotis Repoussis, Gerassimos Panagalis, Meletios Athanasios Dimopoulos
BLOOD ,2007/11/16

11. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance.
Georgiou G, Karali V, Zouvelou C, Kyriakou E, Dimou M, Chrisochoou S, Greka P, Dufexis D, Vervesou E, Dimitriadou E, Efthymiou A, Petrikkos L, Dima K, Lilakos K, Panayiotidis P.
Br J Haematol. 2006 Aug;134(3):302-6. Epub 2006 Jun 20.

12. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E,Michali E, Pouli A, Gika D, Vassou A, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G.
J Clin Oncol. 2007 Aug 1;25(22):3344-9. Epub 2007 Jun 18.

13. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI.
Br J Haematol. 2006 Dec;135(5):688-92.

14. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC,Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC.
Blood. 2005 Sep 15;106(6):2162-8. Epub 2005 May 26.

15. 13q deletion in chronic lymphocytic leukemia: characterization of E4.5, a novel chromosome condensation regulator-like guanine nucleotide exchange factor.
Solomou EE, Sfikakis PP, Kotsi P, Papaioannou M, Karali V, Vervessou E, Hoffbrand AV, Panayiotidis P.
Leuk Lymphoma. 2003 Sep;44(9):1579-85.

16. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
Dimopoulos MA, Hamilos G, Zervas K, Symeonidis A, Kouvatseas G, Roussou P, Gika D, Karmiris T, Bourantas K, Zomas A, Mitsouli C, Xilouri I, Vervessou E, Matsis K, Anagnostopoulos N, Economopoulos T; Greek Myeloma Study Group.
Ann Oncol. 2003 Aug;14(8):1299-305.

17. Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia.
Dimopoulos MA, Zervas C, Zomas A, Hamilos G, Gika D, Efstathiou E, Panayiotidis P, Vervessou E, Anagnostopoulos N, Christakis J.
Clin Lymphoma. 2002 Dec;3(3):163-6.

18. ITD and asp835 mutation of flt-3 gene can occur simultaneously in AML patients.
V Karali, E Dimitriadou, P Kotsi, G Georgiou, E.Vervessou 
Blood, 2002

19. Antithymocyte globulin (ATG) administration in T-ALL patients resistant to chemotherapy
E Dimitriadou, G Georgiou, E Vervessou, A Kokkinos, F Kontopidou, P Panayiotidis
Blood ,2002/11/16

20. A comparison of intravenous vs per OS induction/maintenance in older adult acute myeloid leukemia (AML) patients in two consecutive trials: A study of the Hellenic cooperative group.
N Stavroyianni, X Yataganas, N Anagnostopoulos, M Belegrati, C Bourantas, K Konstantopoulos, E Fragopanagou, N Giannakoulias, A Galanopoulos, T Kalmantis, I Korantzis, A Kouraklis, P Matsouka, T Marinakis, P Panayiotidis, E Papakonstantinou, G Paterakis, Y Rombos, P Roussou, A Symeonides, M Tiniakou, E Triantafyllou, E Vervessou, G Vaiopoulos, N Zoumbos
Blood ,2001

21. Thalidomide and dexamethasone combination for refractory multiple myeloma.
Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N.
Αnnal.Oncol. 2001 Jul;12(7):991-5.

22. Thalidomide and dexamethasone combination for multiple myleoma refractory to dexamethasone-based regimens.
Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N
Blood, 2000

23. High-dose melphalan 180 mg/m (2) with autologous blood stem cell transplantation for multiple myeloma
MA Dimopoulos, C Papadimitriou, E Kostis, V Kouvelis, A Zomas, V Grigoraki, E Vervessou, N Sakarellou, P Panayiotides, N Anagnostopoulos
Blood ,1999


CITATIONS : 595